Previous Article | Next Article ![]()
Antimicrobial Agents and Chemotherapy, July 1998, p. 1847-1849, Vol. 42, No. 7
Département de Microbiologie
Médicale et Infectiologie, Pavillon St-Luc, Centre Hospitalier de
l'Université de Montréal, Montréal, Québec,
Canada H2X 3J4
Received 7 October 1997/Returned for modification 15 January
1998/Accepted 15 April 1998
The susceptibilities of 59 Campylobacter fetus subsp.
fetus isolates to eight antibiotics were studied by the
agar dilution, E-test, and disk diffusion methods. None of the isolates
were Campylobacter fetus
subsp. fetus is a rare human pathogen that causes
extraintestinal infections and bacteremia, mainly in patients with
serious underlying conditions or immunosuppression (2, 22,
25). Systemic C. fetus subsp. fetus
infections often require prolonged parenteral therapy with one or two
antibiotics, and the prognosis may be poor for the compromised host
(2). There is no standardized susceptibility testing method
for this organism (19).
The objectives of this study were to determine Fifty-nine strains were tested by the agar dilution and the disk
diffusion tests with eight antibiotics, 17 of which strains were
isolated in our institution and 42 of which were provided by the
Laboratoire de Santé Publique du Québec. Of the 59 strains, 30 were also tested by the E test for four of the antibiotics. All
strains were previously identified as C. fetus subsp.
fetus based on standard criteria and methodology
(19).
The antibiotics used were ampicillin, gentamicin, erythromycin,
tetracycline, cefotaxime, ciprofloxacin (all from Sigma Chemical Co.,
St. Louis, Mo.), imipenem (Merck Sharp & Dohme, West Point, Pa.), and
meropenem (Zeneca Pharma Inc., Mississauga, Ontario, Canada).
Suspensions of 24- to 48-h blood agar cultures were adjusted to a 0.5 McFarland turbidity standard in Mueller-Hinton broth (BBL Microbiology
Systems) for the disk diffusion and E test methods and diluted 1:10 for
agar dilution. A final inoculum of 104 CFU was applied to
unsupplemented Mueller-Hinton plates (BBL) for agar dilution with a
Cathra 3-mm replicator. The antibiotic concentrations ranged from 0.06 to 128 µg/ml, and a control plate without antibiotic was inoculated
at the beginning of the procedure. All plates were incubated for
48 h at 35°C under microaerophilic conditions (about 5%
O2, 10% CO2, and 85% N2) with gas
generator envelopes (Difco).
A standard method of inoculation was used for disk diffusion and the E
test (21) with the same medium and incubation conditions as
for agar dilution.
For agar dilution, the endpoint was taken as the concentration that
resulted in complete inhibition of visible growth. For the E test, the
MIC was read at the point of intersection between the inhibition
ellipse and the E-test strip. For the disk diffusion test, the
antibiotic concentrations were chosen according to the recommendations
of the National Committee for Clinical Laboratory Standards (NCCLS)
(21). The zone diameters were measured with slipping
calipers. NCCLS susceptibility criteria were used to interpret the
results for aerobic organisms (20, 21), since no such
criteria are available for C. fetus subsp. fetus.
The following quality control strains were used: Staphylococcus
aureus ATCC 29213, S. aureus ATCC 25923, Enterococcus faecalis ATCC 29212, Escherichia
coli ATCC 25922, and Pseudomonas aeruginosa ATCC 27853.
A nitrocefin solution method in microwells was used for All strains were
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Antimicrobial Susceptibility Testing of 59 Strains
of Campylobacter fetus subsp. fetus
![]()
ABSTRACT
Top
Abstract
Text
References
-lactamase producers. All were susceptible to ampicillin,
gentamicin, imipenem, and meropenem as determined by the three methods,
with MICs at which 90% of the isolates are inhibited
(MIC90s) (determined by agar dilution) of 2, 1,
0.06, and
0.12 µg/ml, respectively. Twenty-seven percent of the isolates were
resistant to tetracycline, with complete agreement between the agar
dilution and disk diffusion results. The MIC90s determined
by agar dilution were 2 µg/ml for erythromycin, 1 µg/ml for
ciprofloxacin, and 8 µg/ml for cefotaxime.
![]()
TEXT
Top
Abstract
Text
References
-lactamase production
of 59 strains of C. fetus subsp. fetus isolated
in Québec, Canada, and the antimicrobial susceptibility patterns
of those strains against eight antibiotics. Three methods of
susceptibility testing were compared: agar dilution, disk diffusion,
and the E test.
-lactamase
detection, as previously described by Lachance et al. (13).
S. aureus ATCC 29213 and S. aureus ATCC 25923 were used as positive and negative controls, respectively. Three
Campylobacter jejuni strains in which
-lactamase had
previously been isolated and characterized were also used as positive
controls (14).
-lactamase negative. The percentages of susceptible
strains determined by the three methods are indicated in Table
1 with the corresponding disk diameters
for the susceptible organisms. MIC ranges, the MICs at which 50% of
the isolates are inhibited (MIC50s) and MIC90s
determined by the agar dilution and E-test methods are also indicated.
All isolates were susceptible to ampicillin, gentamicin, imipenem, and
meropenem by the three methods. The lowest MICs were obtained with
gentamicin, imipenem, and meropenem.
TABLE 1.
Susceptibilities of 59 strains of C. fetus
subsp. fetus as determined by agar dilution, disk diffusion,
or E test
There was complete agreement between the agar dilution and disk diffusion test results for tetracycline: 27% of isolates were resistant and 73% were susceptible by both methods.
The percentages of intermediate MICs were 61% for erythromycin, 2% for ciprofloxacin, and 10% for cefotaxime by the agar dilution method. When agar dilution and disk diffusion were compared, minor error rates were 61% with erythromycin, 12% with cefotaxime, and 2% with ciprofloxacin. There was no major or very major error with any of the antibiotics.
Overall agreement of MICs ±1 log2 dilution between the agar dilution and the E-test method (data not shown) was 100% with gentamicin and imipenem, 98% with meropenem, and 90% with ampicillin. An important discrepancy was seen with cefotaxime, to which none of the 30 strains were susceptible by the E test, with 10 and 90% being intermediate and resistant, respectively (compared with 90% of strains being susceptible and 10% being intermediate by the agar dilution method). This was not observed with the control strains, for which MICs were within the expected limits under identical testing conditions. Also, such a difference was not observed between the agar dilution and the disk diffusion tests, whose results were more concordant (90% susceptible by agar dilution and 84% susceptible by disk diffusion).
Few studies of C. fetus subsp. fetus susceptibility have been published over the past 20 years, and in those few, a wide variety of inocula and media have been used (3-6, 9, 11, 12, 17, 26), mostly on a small number of strains (average, 13; range, 2 to 30). Interstudy comparison has therefore been difficult.
Fliegelman et al. (6) and Spelhaug et al. (26)
evaluated
-lactamase production and found no positive strains (of a
combined total of 34 for both studies), which is in agreement with our results. None of our isolates were resistant to ampicillin. The MIC
range obtained was comparable to those in the literature describing tests in which a similar inoculum was used (6, 9, 17, 26). A
small number of resistant strains were reported in studies (3-5) with inocula with McFarland standards ranging from 1 to 3, but none of these studies reported
-lactamase testing.
Treatment failures have been reported in a recent review
(16), but patients described in that work suffered from
severe endovasculitis and associated conditions. Ampicillin has been
considered a reasonable choice whenever susceptibility testing could be
done (2, 7). In two studies (17, 26), its
bactericidal activity was considered superior to those of
expanded-spectrum cephalosporins, such as cefotaxime, but inferior to
those of gentamicin and imipenem.
Similar to our findings, gentamicin (3-6, 9, 12, 17, 26), imipenem (17, 26), and meropenem (12) had the lowest MICs in previous studies, and no resistance has yet been reported. Gentamicin and imipenem are considered the preferred treatments for severe systemic infections (2, 9, 18), and imipenem was suggested as the first-choice agent for dealing with central nervous system infections (17).
Our results showed a high percentage of intermediate MICs of erythromycin. This was also previously observed (4-6, 9, 12) with C. fetus subsp. fetus. Several therapeutic failures or relapses were reported with that agent, sometimes with strains initially shown to be sensitive, and it is no longer a recommended treatment for systemic C. fetus subsp. fetus infections (2, 7, 16, 23).
Reported resistance to tetracycline has been low, occurring in one or two strains and in only one study (9), in contrast with our finding that 27% of our isolates were resistant to tetracycline. C. jejuni and Campylobacter coli tetracycline resistance mediated by a plasmid with demonstrated transmissibility from C. jejuni to C. fetus (29) has been described by Taylor et al. (27, 29).
Few of the reviewed studies reported ciprofloxacin resistance (9, 12, 24). C. fetus subsp. fetus quinolone resistance mediated by a mutation on the gyrase gene has been described (28). Two cases of bacteremic infection with quinolone-resistant C. fetus subsp. fetus in immunosuppressed patients who had prior contact with the antibiotic have been reported (15).
While a majority of our isolates were sensitive to cefotaxime by the disk diffusion and the agar dilution methods, the MIC50s and MIC90s for the isolates were at the susceptibility limit of 8 µg/ml. Intermediate MIC90s of cefotaxime were found in five studies (9, 11, 12, 17, 26), and its bactericidal activity was generally lower than those of ampicillin, gentamicin, and imipenem (17, 26). Although expanded-spectrum cephalosporins were mentioned as an alternative choice in treating C. fetus subsp. fetus systemic infections (2), we tend to believe that cefotaxime should be used with caution, keeping in mind that its activity could be only moderate. E-test susceptibility testing for that agent seems unreliable with C. fetus subsp. fetus, and we do not recommend its use until further study can be done.
Overall agreement among the three testing methods with the antimicrobial agents most often used clinically in treating C. fetus subsp. fetus infections (ampicillin, gentamicin, imipenem, and meropenem) was good. None of the MICs for tested isolates were intermediate or resistant, and had they been, it still cannot be concluded that results would have been comparable. However, the disk diffusion and E-test methods have been evaluated in comparison with agar dilution for other Campylobacter species (1, 8, 10) of which resistant or intermediate strains were involved, and results showed a high percentage of agreement in each category for most of the antibiotics. The E test and disk diffusion thus could be acceptable and convenient methods of susceptibility testing when agar dilution cannot be performed.
| |
ACKNOWLEDGMENTS |
|---|
We thank Manon Lorange from the Laboratoire de Santé Publique du Québec, who graciously provided us with some of the bacterial strains used in this study; Brigite Chevrier and Angela Gurd for secretarial services; and Zeneca Pharma Inc., which contributed to the realization of this project.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Département de Microbiologie Médicale et Infectiologie, Pavillon St-Luc, CHUM, 1058 rue St-Denis, Montréal, Québec, Canada, H2X 3J4. Phone: (514) 281-2100. Fax: (514) 281-2443. E-mail: cgaudro{at}cam.org.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Baker, C. N. 1992. The E-Test and Campylobacter jejuni. Diagn. Microbiol. Infect. Dis. 15:469-472[Medline]. |
| 2. | Blaser, M. J. 1995. Campylobacter and related species, p. 1948-1956. In G. L. Mandell, J. A. Bennett, and R. Dolin (ed.), Principles and practice in infectious diseases, 4th ed. Churchill Livingstone, New York, N.Y. |
| 3. |
Butzler, J. P.,
P. Dekeyser, and T. Lafontaine.
1974.
Susceptibility of related vibrios and Vibrio fetus to twelve antibiotics.
Antimicrob. Agents Chemother.
5:86-89 |
| 4. |
Chow, A. W.,
V. Patten, and D. Bednorz.
1978.
Susceptibility of Campylobacter fetus to twenty-two antimicrobial agents.
Antimicrob. Agents Chemother.
13:416-418 |
| 5. |
Edmonds, P.,
C. M. Patton,
T. J. Barrett,
G. K. Morris,
A. G. Steigerwalt, and D. J. Brenner.
1985.
Biochemical and genetic characteristics of atypical Campylobacter fetus subsp. fetus strains isolated from humans in the United States.
J. Clin. Microbiol.
21:936-940 |
| 6. |
Fliegelman, R. M.,
R. M. Petrak,
L. J. Goodman,
J. Segreti,
G. M. Trenholme, and R. L. Kaplan.
1985.
Comparative in vitro activities of twelve antimicrobial agents against Campylobacter species.
Antimicrob. Agents Chemother.
27:429-430 |
| 7. |
Francioli, P.,
J. Herzstein,
J.-P. Grob,
J.-J. Vallotton,
G. Mombelli, and M. P. Glauser.
1985.
Campylobacter fetus bacteremia.
Arch. Intern. Med.
145:289-292 |
| 8. |
Gaudreau, C., and H. Gilbert.
1997.
Comparison of disc diffusion and agar dilution methods for antibiotic susceptibility testing of Campylobacter jejuni subsp. jejuni and Campylobacter coli.
J. Antimicrob. Chemother.
39:707-712 |
| 9. |
Goossens, H.,
L. V. Coignau, and J. P. Butzler.
1989.
In-vitro evaluation of combinations against Campylobacter fetus.
J. Antimicrob. Chemother.
24:195-201 |
| 10. |
Huang, M. B.,
C. N. Baker,
S. Banerjee, and F. C. Tenover.
1992.
Accuracy of the E test for determining antimicrobial susceptibilities of staphylococci, enterococci, Campylobacter jejuni, and gram-negative bacteria resistant to antimicrobial agents.
J. Clin. Microbiol.
30:3243-3248 |
| 11. |
Karmali, M. A.,
S. De Grandis, and P. C. Fleming.
1980.
Antimicrobial susceptibility of Campylobacter jejuni and Campylobacter fetus subsp. fetus to eight cephalosporins with special reference to species differentiation.
Antimicrob. Agents Chemother.
18:948-951 |
| 12. | Kwon, S.-Y., D. H. Cho, S. Y. Lee, K. Lee, and Y. Chong. 1994. Antimicrobial susceptibility of Campylobacter fetus subsp. fetus isolated from blood and synovial fluid. Yonsei Med. J. 35:314-319[Medline]. |
| 13. |
Lachance, N.,
C. Gaudreau,
F. Lamothe, and F. Turgeon.
1993.
Susceptibilities of -lactamase-positive and -negative strains of Campylobacter coli to -lactam agents.
Antimicrob. Agents Chemother.
37:1174-1176 |
| 14. |
Lachance, N.,
C. Gaudreau,
F. Lamothe, and L. A. Larivière.
1991.
Role of -lactamase of Campylobacter jejuni in resistance to -lactam agents.
Antimicrob. Agents Chemother.
35:813-818 |
| 15. | Meier, P. A., D. P. Dooley, and J. H. Jorgensen. 1993. Development of quinolone-resistant Campylobacter fetus bacteremia in HIV-infected patients. Clin. Infect. Dis. 17:547. |
| 16. | Montero, A., X. Corbella, J. A. Lopez, M. Santin, and I.-H. Ballon. 1997. Campylobacter fetus-associated aneurysms: report of a case involving the popliteal artery and review of the literature. Clin. Infect. Dis. 24:1019-1020[Medline]. |
| 17. | Morooka, T., and T. Oda. 1989. In vitro evaluation of antibiotics for treatment of meningitis caused by Campylobacter fetus subspecies fetus. Pediatr. Infect. Dis. J. 8:653-654[Medline]. |
| 18. | Morrison, V. A., B. K. Lloyd, J. K. S. Chia, and C. U. Tuazon. 1990. Cardiovascular and bacteremic manifestations of Campylobacter fetus infection: case report and review. Rev. Infect. Dis. 12:387-392[Medline]. |
| 19. | Nachamkin, I. 1995. Campylobacter and Arcobacter, p. 483-491. In P. R. Murray, E. J. Baron, M. A. Pfaller, F. C. Tenover, and R. H. Yolken (ed.), Manual of clinical microbiology, 6th ed. American Society for Microbiology, Washington, D.C. |
| 20. | National Committee for Clinical Laboratory Standards. 1997. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 4th ed. Approved standard M7-A4. National Committee for Clinical Laboratory Standards, Wayne, Pa. |
| 21. | National Committee for Clinical Laboratory Standards. 1997. Performance standard for antimicrobial disk susceptibility tests, 6th ed. Approved standard M2-A6. National Committee for Clinical Laboratory Standards, Wayne, Pa. |
| 22. |
Penner, J. L.
1988.
The genus Campylobacter: a decade of progress.
Clin. Microbiol. Rev.
1:157-172 |
| 23. | Righter, J., W. A. Wells, G. D. Hart, and D. J. McNeely. 1983. Relapsing septicemia caused by Campylobacter fetus subsp. fetus. Can. Med. Assoc. J. 128:686-689[Medline]. |
| 24. |
Sánchez, R.,
V. Fernández-Baca,
M. D. Díaz,
P. Muñoz,
M. Rodríguez-Créixems, and E. Bouza.
1994.
Evolution of susceptibilities of Campylobacter spp. to quinolones and macrolides.
Antimicrob. Agents Chemother.
38:1879-1882 |
| 25. | Skirrow, M. B., D. M. Jones, E. Sutcliffe, and J. Benjamin. 1993. Campylobacter bacteremia in England and Wales, 1981-91. Epidemiol. Infect. 110:567-573[Medline]. |
| 26. | Spelhaug, D. R., M. J. R. Gilchrist, and J. A. Washington. 1981. Bactericidal activity of antibiotics against Campylobacter fetus subspecies intestinalis. J. Infect. Dis. 143:500[Medline]. |
| 27. |
Taylor, D. E., and P. Courvalin.
1988.
Mechanisms of antibiotic resistance in Campylobacter species.
Antimicrob. Agents Chemother.
32:1107-1112 |
| 28. | Taylor, D. E., and A. S.-S. Chau. 1997. Cloning and nucleotide sequence of the gyrA gene from Campylobacter fetus subsp. fetus ATCC 27374 and characterization of ciprofloxacin-resistant laboratory and clinical isolates. Antimicrob. Agents Chemother. 41:665-671[Abstract]. |
| 29. |
Taylor, D. E.,
R. S. Garner, and B. J. Allan.
1983.
Characterization of tetracycline resistance plasmids from Campylobacter jejuni and Campylobacter coli.
Antimicrob. Agents Chemother.
24:930-935 |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»